2/11
10:39 am
tlsa
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease [Yahoo! Finance]
Medium
Report
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease [Yahoo! Finance]
2/11
09:15 am
tlsa
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
Low
Report
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
1/23
03:00 pm
tlsa
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
Medium
Report
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
1/23
08:54 am
tlsa
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
High
Report
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
1/22
04:50 pm
tlsa
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab [Yahoo! Finance]
Medium
Report
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab [Yahoo! Finance]
1/22
04:05 pm
tlsa
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
Medium
Report
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
1/10
08:00 am
tlsa
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
High
Report
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
1/8
07:00 am
tlsa
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
Low
Report
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
12/17
07:32 am
tlsa
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab [Yahoo! Finance]
Low
Report
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab [Yahoo! Finance]
12/17
07:00 am
tlsa
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
Low
Report
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
12/4
07:15 am
tlsa
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers [Yahoo! Finance]
Low
Report
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers [Yahoo! Finance]
12/4
07:00 am
tlsa
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers
Low
Report
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers
11/19
07:06 am
tlsa
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association [Yahoo! Finance]
Medium
Report
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association [Yahoo! Finance]
11/19
07:00 am
tlsa
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
Medium
Report
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association